Rafferty Asset Management, LLC Lyell Immunopharma, Inc. Transaction History

Rafferty Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.45 - $3.35 $144,415 - $333,649	99,597 Added 30.62%	424,886 $624,000
Q2 2023 Aug 11, 2023	SELL	$1.89 - $3.86 $342,054 - $698,586	-180,981 Reduced 35.75%	325,289 $1.03 Million
Q1 2023 May 11, 2023	SELL	$1.97 - $3.58 $147,933 - $268,832	-75,093 Reduced 12.92%	506,270 $1.19 Million
Q4 2022 Feb 13, 2023	BUY	$2.78 - $8.09 $1.04 Million - $3.03 Million	374,963 Added 181.67%	581,363 $2.02 Million
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $1.14 Million - $1.71 Million	206,400 New	206,400 $1.51 Million

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.